Kolon Life Science Current Assets
The Current Assets of Kolon Life Science (102940.KQ) as of Nov 3, 2026 is 56.24 B KRW. In the previous year, Current Assets was 97.76 B KRW — a change of -42.48% (lower).
Get this data via API
Financial Data API
Current Assets
56.24 BKRW
YoY
-42.48%
Last updated:
Current Assets of Kolon Life Science is 2025 56.24 B KRW. Current Assets of Kolon Life Science was 2024 97.76 B KRW. It decreases by -42.48% lower compared to the previous year.
The Kolon Life Science Current Assets history
3 Years
10 Years
25 Years
Max
Current Assets
Date
Current Assets
Jan 1, 2018
102.88 B KRW
Jan 1, 2019
86.77 B KRW
Jan 1, 2020
93.38 B KRW
Jan 1, 2021
94.29 B KRW
Jan 1, 2022
104.91 B KRW
Jan 1, 2023
100.89 B KRW
Jan 1, 2024
97.76 B KRW
Jan 1, 2025
56.24 B KRW
| YEAR | Current Assets | YoY |
|---|---|---|
| 56.24 BKRW | -42.48% | |
| 97.76 BKRW | -3.10% | |
| 100.89 BKRW | -3.83% | |
| 104.91 BKRW | +11.26% | |
| 94.29 BKRW | +0.98% | |
| 93.38 BKRW | +7.62% | |
| 86.77 BKRW | -15.66% | |
| 102.88 BKRW | -30.37% | |
| 147.75 BKRW | -23.96% | |
| 194.31 BKRW | +140.91% | |
| 80.66 BKRW | +29.17% | |
| 62.44 BKRW | -28.10% | |
| 86.85 BKRW | +41.76% | |
| 61.26 BKRW | +5.13% | |
| 58.27 BKRW | -1.24% | |
| 59.01 BKRW | +28.19% | |
| 46.03 BKRW | +40.40% | |
| 32.79 BKRW | +28.40% | |
| 25.53 BKRW | +25.25% | |
| 20.39 BKRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Kolon Life Science Stock analysis
What does Kolon Life Science do? KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment.
The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space.
KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options. Kolon Life Science is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Kolon Life Science stock
Current Assets of Kolon Life Science is 56.24 B KRW in 2025.
Current Assets of Kolon Life Science changed from 97.76 B KRW to 56.24 B KRW, representing a -42.48% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Assets Kolon Life Science since 2006 – with annual values, charts, and detailed analysis.
Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.
Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Kolon Life Science historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — Kolon Life Science
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Kolon Life Science
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth